"Imaging has continually evolved the way new and novel therapies are evaluated. Using imaging as a measure of disease whether, qualitative or quantitative, provides researchers with more sensitive measures for study outcomes. When assessing neurodegeneration, quantitative measurements capable of detecting small changes in early disease provide researchers with the information to target therapies aimed at slowing disease progression before patients experience debilitating symptoms."

What are some transformative breakthroughs that have driven precision medicine efforts?

"A scientist that I admire tremendously is one that I have had the distinct honor of calling both mentor and colleague. Throughout my career, I have had the benefit of working under the guidance and eventually, alongside, Dr. John Seibyl. Dr. Seibyl has been a pioneer in the development and use of novel radiotracers to identify and measure neurodegenerative disease for well over 25 years. Throughout his career, he has worked tirelessly to advance the use of imaging and novel tracers for monitoring disease progression and as a tool to measure drug efficacy. In addition to his tireless dedication to the advancement of imaging as a tool, Dr. Seibyl has always been a kind and patient teacher to many, with an unwavering humor and kind-heartedness."